2-{2-[(1H-benzimidazol-2-ylmethyl)sulfanyl]-1H-benzimidazol-1-yl}ethyl phenyl ether

2-{2-[(1H-benzimidazol-2-ylmethyl)sulfanyl]-1H-benzimidazol-1-yl}ethyl phenyl ether Chemische Eigenschaften,Einsatz,Produktion Methoden

• Verwenden

  GY1-22 is an inhibitor of DNAJA1-mutP53R175H interacting pocket. GY1-22 can be used for the research of cancer[1].

• in vivo

  The LD₅₀ of GY1-22 in rats is 1240 mg/kg. Dosage of 10 mg/kg (i.p.; daily for 2 weeks) does not exhibit any toxicity grossly or histologically in mice^[1].
  GY1-22 (1 mg/kg; i.p.; daily for 2 weeks) inhibits mutp53-driven P03 pancreatic cancer cell growth in mice^[1].

  Animal Model:	C57BL/6J mice implanted with P03 cells[1]
  Dosage:	1 mg/kg
  Administration:	IP, daily for 2 weeks
  Result:	Showed a significant inhibition of in vivo tumor growth, which was comparable with P03 DNAJA1 knockout line.

• Einzelnachweise

  [1] Tong X, et al. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. J Biol Chem. 2021 Jan-Jun;296:100098. DOI:10.1074/jbc.RA120.014749

2-{2-[(1H-benzimidazol-2-ylmethyl)sulfanyl]-1H-benzimidazol-1-yl}ethyl phenyl ether Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(4)Suppliers